Patient characteristics according to transplant type
| Variable . | Blood stem cells transplant . | Bone marrow transplant . | P value . |
|---|---|---|---|
| Total no. of patients | [288] | [536] | .24 |
| Median age (range), y | 39 (20-61) [288] | 37 (20-63) [536] | .06 |
| Male sex | 159 (55) [288] | 288 (54) [536] | .68 |
| Karnofsky score < 90% | 50 (19) [264] | 112 (21) [534] | .50 |
| Disease, stage | [288] | [536] | .08 |
| AML, 1st CR | 95 (33) | 155 (29) | |
| AML, 2nd CR | 26 (9) | 29 (5) | |
| ALL, 1st CR | 25 (9) | 56 (10) | |
| ALL, 2nd CR | 13 (4) | 18 (4) | |
| CML, 1st CP | 101 (35) | 245 (46) | |
| CML, 2nd CP/AP | 28 (10) | 33 (6) | |
| Prior busulfan for CML | 12 (9) [129] | 27 (10) [277] | .42 |
| Prior interferon for CML | 65 (50) [129] | 131 (47) [277] | .16 |
| TBI for conditioning | 178 (62) [288] | 224 (42) [536] | < .0001 |
| Conditioning regimen | [288] | [536] | < .0001 |
| Cy + TBI ± other | 154 (53) | 162 (30) | |
| Busulfan + Cy ± other | 106 (37) | 289 (54) | |
| TBI ± other | 24 (8) | 56 (10) | |
| Cy ± other | — | 7 (2) | |
| Other | 4 (2) | 22 (4) | |
| G-CSF or GM-CSF in 1st 7 d after transplantation | 97 (37) [264] | 112 (21) [531] | < .001 |
| GVHD prophylaxis | [287] | [535] | < .001 |
| CsA ± other | 94 (33) | 56 (10) | |
| CsA + MTX ± corticosteroids | 174 (61) | 472 (88) | |
| FK506 ± other | 13 (4) | 1 (< 1) | |
| Other | 6 (2) | 6 (1) | |
| Region | [288] | [536] | < .001 |
| North America | 105 (37) | 165 (31) | |
| Europe | 152 (53) | 226 (42) | |
| Asia | 21 (7) | 59 (11) | |
| Australia/New Zealand | 7 (2) | 27 (5) | |
| Other | 2 (1) | 60 (11) | |
| Median follow-up, mo | 12 (3-39) [288] | 12 (3-40) [536] | .72 |
| Variable . | Blood stem cells transplant . | Bone marrow transplant . | P value . |
|---|---|---|---|
| Total no. of patients | [288] | [536] | .24 |
| Median age (range), y | 39 (20-61) [288] | 37 (20-63) [536] | .06 |
| Male sex | 159 (55) [288] | 288 (54) [536] | .68 |
| Karnofsky score < 90% | 50 (19) [264] | 112 (21) [534] | .50 |
| Disease, stage | [288] | [536] | .08 |
| AML, 1st CR | 95 (33) | 155 (29) | |
| AML, 2nd CR | 26 (9) | 29 (5) | |
| ALL, 1st CR | 25 (9) | 56 (10) | |
| ALL, 2nd CR | 13 (4) | 18 (4) | |
| CML, 1st CP | 101 (35) | 245 (46) | |
| CML, 2nd CP/AP | 28 (10) | 33 (6) | |
| Prior busulfan for CML | 12 (9) [129] | 27 (10) [277] | .42 |
| Prior interferon for CML | 65 (50) [129] | 131 (47) [277] | .16 |
| TBI for conditioning | 178 (62) [288] | 224 (42) [536] | < .0001 |
| Conditioning regimen | [288] | [536] | < .0001 |
| Cy + TBI ± other | 154 (53) | 162 (30) | |
| Busulfan + Cy ± other | 106 (37) | 289 (54) | |
| TBI ± other | 24 (8) | 56 (10) | |
| Cy ± other | — | 7 (2) | |
| Other | 4 (2) | 22 (4) | |
| G-CSF or GM-CSF in 1st 7 d after transplantation | 97 (37) [264] | 112 (21) [531] | < .001 |
| GVHD prophylaxis | [287] | [535] | < .001 |
| CsA ± other | 94 (33) | 56 (10) | |
| CsA + MTX ± corticosteroids | 174 (61) | 472 (88) | |
| FK506 ± other | 13 (4) | 1 (< 1) | |
| Other | 6 (2) | 6 (1) | |
| Region | [288] | [536] | < .001 |
| North America | 105 (37) | 165 (31) | |
| Europe | 152 (53) | 226 (42) | |
| Asia | 21 (7) | 59 (11) | |
| Australia/New Zealand | 7 (2) | 27 (5) | |
| Other | 2 (1) | 60 (11) | |
| Median follow-up, mo | 12 (3-39) [288] | 12 (3-40) [536] | .72 |
Values in square brackets are the numbers of patients evaluated in each major category, values in parentheses are percentages of patients unless otherwise indicated, and all other values are numbers of patients unless otherwise indicated.
AML indicates acute myelogenous leukemia; CR, complete remission; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; TBI, total-body irradiation; Cy, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GVHD, graft versus host disease; CsA, cyclosporine; and MTX, methotrexate.